{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:45:51Z","timestamp":1787849151376,"version":"build-2784847793"},"reference-count":100,"publisher":"Siapec Servizi Srl","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-1531","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:31:08Z","timestamp":1775737868000},"page":"546-558","source":"Crossref","is-referenced-by-count":2,"title":["Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+\/HER2- metastatic breast cancer"],"prefix":"10.32074","volume":"117","author":[{"given":"Umberto","family":"Malapelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Buglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"de Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Scatena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Scatolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"10.32074\/1591-951X-1531_ref1","doi-asserted-by":"crossref","unstructured":"Li Q, Jiang B, Guo J, et al. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4\/6 Kinase Inhibitors. Cancer Discov. 2022;12(2):356-71. Epub 20210920. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1726. PubMed PMID: 34544752; PubMed Central PMCID: PMC8831444.","DOI":"10.1158\/2159-8290.CD-20-1726"},{"key":"10.32074\/1591-951X-1531_ref2","unstructured":"Razavi P, Chang MT, Xu G, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018;34(3):427-38.e6. Epub 2018\/09\/12. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.008. PubMed PMID: 30205045; PubMed Central PMCID: PMC6327853."},{"key":"10.32074\/1591-951X-1531_ref3","doi-asserted-by":"crossref","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-4. https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0095. PubMed PMID: 22588877; PubMed Central PMCID: PMC3956037.","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"10.32074\/1591-951X-1531_ref4","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. Epub 20130402. https:\/\/doi.org\/10.1126\/scisignal.2004088. PubMed PMID: 23550210; PubMed Central PMCID: PMC4160307.","DOI":"10.1126\/scisignal.2004088"},{"key":"10.32074\/1591-951X-1531_ref5","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861-7. https:\/\/doi.org\/10.1158\/0008-5472.can-23-0816. PubMed PMID: 37668528; PubMed Central PMCID: PMC10690089."},{"key":"10.32074\/1591-951X-1531_ref6","doi-asserted-by":"crossref","unstructured":"Martorana F, Motta G, Pavone G, et al. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? Front Pharmacol. 2021;12:662232. Epub 20210429. https:\/\/doi.org\/10.3389\/fphar.2021.662232. PubMed PMID: 33995085; PubMed Central PMCID: PMC8118639.","DOI":"10.3389\/fphar.2021.662232"},{"key":"10.32074\/1591-951X-1531_ref7","doi-asserted-by":"crossref","unstructured":"Fusco N, Malapelle U, Fassan M, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Front Oncol. 2021;11:644737. Epub 20210325. https:\/\/doi.org\/10.3389\/fonc.2021.644737. PubMed PMID: 33842357; PubMed Central PMCID: PMC8027489.","DOI":"10.3389\/fonc.2021.644737"},{"key":"10.32074\/1591-951X-1531_ref8","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208-17. Epub 20201125. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.011. PubMed PMID: 33246021.","DOI":"10.1016\/j.annonc.2020.11.011"},{"key":"10.32074\/1591-951X-1531_ref9","doi-asserted-by":"crossref","unstructured":"Blair HA. Inavolisib: First Approval. Drugs. 2025;85(2):271-8. Epub 20250128. https:\/\/doi.org\/10.1007\/s40265-024-02136-y. PubMed PMID: 39873916.","DOI":"10.1007\/s40265-024-02136-y"},{"key":"10.32074\/1591-951X-1531_ref10","doi-asserted-by":"crossref","unstructured":"Shirley M. Capivasertib: First Approval. Drugs. 2024;84(3):337-46. https:\/\/doi.org\/10.1007\/s40265-024-01998-6. PubMed PMID: 38388873.","DOI":"10.1007\/s40265-024-01998-6"},{"key":"10.32074\/1591-951X-1531_ref11","doi-asserted-by":"crossref","unstructured":"Miricescu D, Totan A, Stanescu S, II. PI3K\/AKT\/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci. 2020;22(1). Epub 20201226. https:\/\/doi.org\/10.3390\/ijms22010173. PubMed PMID: 33375317; PubMed Central PMCID: PMC7796017.","DOI":"10.3390\/ijms22010173"},{"key":"10.32074\/1591-951X-1531_ref12","doi-asserted-by":"crossref","unstructured":"Fusco N, Sajjadi E, Venetis K, et al. PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? Genes (Basel). 2020;11(7). Epub 20200628. https:\/\/doi.org\/10.3390\/genes11070719. PubMed PMID: 32605290; PubMed Central PMCID: PMC7397204.","DOI":"10.3390\/genes11070719"},{"key":"10.32074\/1591-951X-1531_ref13","doi-asserted-by":"crossref","unstructured":"Kim M, Kim J, Seo AN, et al. Comparison of immunohistochemistry and next-generation sequencing results in oncogenic PTEN missense mutations. Pathol Res Pract. 2023;251:154879. Epub 20231010. https:\/\/doi.org\/10.1016\/j.prp.2023.154879. PubMed PMID: 37862920.","DOI":"10.1016\/j.prp.2023.154879"},{"key":"10.32074\/1591-951X-1531_ref14","doi-asserted-by":"crossref","unstructured":"Pankiw M, Brezden-Masley C, Charames GS. Comprehensive genomic profiling for oncological advancements by precision medicine. Med Oncol. 2023;41(1):1. Epub 20231122. https:\/\/doi.org\/10.1007\/s12032-023-02228-x. PubMed PMID: 37993657.","DOI":"10.1007\/s12032-023-02228-x"},{"key":"10.32074\/1591-951X-1531_ref15","doi-asserted-by":"crossref","unstructured":"Venetis K, Pepe F, Munzone E, et al. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+\/HER2- Breast Cancer. Cells. 2022;11(22). Epub 20221109. https:\/\/doi.org\/10.3390\/cells11223545. PubMed PMID: 36428975; PubMed Central PMCID: PMC9688837.","DOI":"10.3390\/cells11223545"},{"key":"10.32074\/1591-951X-1531_ref16","doi-asserted-by":"crossref","unstructured":"Hsiao SJ, Sireci AN, Pendrick D, et al. Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology. JCO Precis Oncol. 2020;4:1038-48. https:\/\/doi.org\/10.1200\/PO.20.00048. PubMed PMID: 35050771.","DOI":"10.1200\/PO.20.00048"},{"key":"10.32074\/1591-951X-1531_ref17","doi-asserted-by":"crossref","unstructured":"Corn\u00e9 J, Le Du F, Quillien V, et al. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients. Sci Rep. 2021;11(1):17316. Epub 20210827. https:\/\/doi.org\/10.1038\/s41598-021-96644-6. PubMed PMID: 34453076; PubMed Central PMCID: PMC8397758.","DOI":"10.1038\/s41598-021-96644-6"},{"key":"10.32074\/1591-951X-1531_ref18","doi-asserted-by":"crossref","unstructured":"Schmidt C, St\u00f6hr R, Dimitrova L, et al. Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue. J Mol Diagn. 2024;26(7):624-37. Epub 20240430. https:\/\/doi.org\/10.1016\/j.jmoldx.2024.04.003. PubMed PMID: 38697471.","DOI":"10.1016\/j.jmoldx.2024.04.003"},{"key":"10.32074\/1591-951X-1531_ref19","doi-asserted-by":"crossref","unstructured":"Rolfo C, Mack P, Scagliotti GV, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16(10):1647-62. Epub 20210708. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.017. PubMed PMID: 34246791.","DOI":"10.1016\/j.jtho.2021.06.017"},{"key":"10.32074\/1591-951X-1531_ref20","doi-asserted-by":"crossref","unstructured":"Ranghiero A, Frascarelli C, Cursano G, et al. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing. Cytopathology. 2023. Epub 20230828. https:\/\/doi.org\/10.1111\/cyt.13295. PubMed PMID: 37640801.","DOI":"10.1111\/cyt.13295"},{"key":"10.32074\/1591-951X-1531_ref21","doi-asserted-by":"crossref","unstructured":"Tokunaga E, Iwata H, Itoh M, et al. Capivasertib and fulvestrant for patients with HR-positive\/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast Cancer. 2025;32(1):132-43. Epub 20241008. https:\/\/doi.org\/10.1007\/s12282-024-01640-z. PubMed PMID: 39379782; PubMed Central PMCID: PMC11717841.","DOI":"10.1007\/s12282-024-01640-z"},{"key":"10.32074\/1591-951X-1531_ref22","doi-asserted-by":"crossref","unstructured":"Rugo HS, Oliveira M, Howell SJ, et al. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open. 2024;9(9):103697. Epub 20240905. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103697. PubMed PMID: 39241495; PubMed Central PMCID: PMC11406080.","DOI":"10.1016\/j.esmoop.2024.103697"},{"key":"10.32074\/1591-951X-1531_ref23","doi-asserted-by":"crossref","unstructured":"Juric D, Kalinsky K, Turner NC, et al. First-line inavolisib\/placebo + palbociclib + fulvestrant (Inavo\/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced\/metastatic breast cancer who relapsed during\/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. Journal of Clinical Oncology. 2024;42(16_suppl):1003-. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1003.","DOI":"10.1200\/JCO.2024.42.16_suppl.1003"},{"key":"10.32074\/1591-951X-1531_ref24","doi-asserted-by":"crossref","unstructured":"Turner NC, Im SA, Saura C, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024;391(17):1584-96. https:\/\/doi.org\/10.1056\/NEJMoa2404625. PubMed PMID: 39476340.","DOI":"10.1056\/NEJMoa2404625"},{"key":"10.32074\/1591-951X-1531_ref25","doi-asserted-by":"crossref","unstructured":"Cetin B, Wabl CA, Gumusay O. CDK4\/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncol. 2022;18(9):1143-57. Epub 20220209. https:\/\/doi.org\/10.2217\/fon-2021-0842. PubMed PMID: 35137602.","DOI":"10.2217\/fon-2021-0842"},{"key":"10.32074\/1591-951X-1531_ref26","doi-asserted-by":"crossref","unstructured":"Roberto M, Astone A, Botticelli A, et al. CDK4\/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers (Basel). 2021;13(2). Epub 20210118. https:\/\/doi.org\/10.3390\/cancers13020332. PubMed PMID: 33477469; PubMed Central PMCID: PMC7830463.","DOI":"10.3390\/cancers13020332"},{"key":"10.32074\/1591-951X-1531_ref27","doi-asserted-by":"crossref","unstructured":"M\u00fcller C, Kiver V, Solomayer EF, et al. CDK4\/6 Inhibitors in Advanced HR+\/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis. Breast Care (Basel). 2023;18(1):31-41. Epub 20221206. https:\/\/doi.org\/10.1159\/000527917. PubMed PMID: 36876172; PubMed Central PMCID: PMC9982335.","DOI":"10.1159\/000527917"},{"key":"10.32074\/1591-951X-1531_ref28","doi-asserted-by":"crossref","unstructured":"Guarducci C, Bonechi M, Boccalini G, et al. Mechanisms of Resistance to CDK4\/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care (Basel). 2017;12(5):304-8. Epub 20171027. https:\/\/doi.org\/10.1159\/000484167. PubMed PMID: 29234249; PubMed Central PMCID: PMC5704709.","DOI":"10.1159\/000484167"},{"key":"10.32074\/1591-951X-1531_ref29","doi-asserted-by":"crossref","unstructured":"Stanciu IM, Parosanu AI, Orlov-Slavu C, et al. Mechanisms of Resistance to CDK4\/6 Inhibitors and Predictive Biomarkers of Response in HR+\/HER2-Metastatic Breast Cancer-A Review of the Literature. Diagnostics (Basel). 2023;13(5). Epub 20230305. https:\/\/doi.org\/10.3390\/diagnostics13050987. PubMed PMID: 36900131; PubMed Central PMCID: PMC10000620.","DOI":"10.3390\/diagnostics13050987"},{"key":"10.32074\/1591-951X-1531_ref30","doi-asserted-by":"crossref","unstructured":"Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of Resistance to CDK4\/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022;28(5):821-30. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-2947. PubMed PMID: 34725098.","DOI":"10.1158\/1078-0432.CCR-21-2947"},{"key":"10.32074\/1591-951X-1531_ref31","doi-asserted-by":"crossref","unstructured":"Gomatou G, Trontzas I, Ioannou S, Drizou M, Syrigos N, Kotteas E. Mechanisms of resistance to cyclin-dependent kinase 4\/6 inhibitors. Mol Biol Rep. 2021;48(1):915-25. Epub 20210107. https:\/\/doi.org\/10.1007\/s11033-020-06100-3. PubMed PMID: 33409716.","DOI":"10.1007\/s11033-020-06100-3"},{"key":"10.32074\/1591-951X-1531_ref32","doi-asserted-by":"crossref","unstructured":"Garrido-Castro AC, Goel S. CDK4\/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. Curr Breast Cancer Rep. 2017;9(1):26-33. Epub 20170201. https:\/\/doi.org\/10.1007\/s12609-017-0232-0. PubMed PMID: 28479958; PubMed Central PMCID: PMC5414585.","DOI":"10.1007\/s12609-017-0232-0"},{"key":"10.32074\/1591-951X-1531_ref33","doi-asserted-by":"crossref","unstructured":"Palafox M, Monserrat L, Bellet M, et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER(+) breast cancer. Nat Commun. 2022;13(1):5258. Epub 20220907. https:\/\/doi.org\/10.1038\/s41467-022-32828-6. PubMed PMID: 36071033; PubMed Central PMCID: PMC9452562.","DOI":"10.1038\/s41467-022-34580-3"},{"key":"10.32074\/1591-951X-1531_ref34","doi-asserted-by":"crossref","unstructured":"Condorelli R, Spring L, O\u2019Shaughnessy J, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29(3):640-5. https:\/\/doi.org\/10.1093\/annonc\/mdx784. PubMed PMID: 29236940.","DOI":"10.1093\/annonc\/mdx784"},{"key":"10.32074\/1591-951X-1531_ref35","doi-asserted-by":"crossref","unstructured":"Kim S, Armand J, Safonov A, et al. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer. Cell Rep. 2023;42(11):113198. Epub 20231021. https:\/\/doi.org\/10.1016\/j.celrep.2023.113198. PubMed PMID: 37865915; PubMed Central PMCID: PMC10757862.","DOI":"10.1016\/j.celrep.2023.113198"},{"key":"10.32074\/1591-951X-1531_ref36","doi-asserted-by":"crossref","unstructured":"Guarducci C, Bonechi M, Benelli M, et al. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer. 2018;4:38. Epub 20181128. https:\/\/doi.org\/10.1038\/s41523-018-0092-4. PubMed PMID: 30511015; PubMed Central PMCID: PMC6261939.","DOI":"10.1038\/s41523-018-0092-4"},{"key":"10.32074\/1591-951X-1531_ref37","doi-asserted-by":"crossref","unstructured":"Wen O, Wolff SC, Stallaert W, Li D, Purvis JE, Zikry TM. Spherical Manifolds Capture Drug-Induced Changes in Tumor Cell Cycle Behavior. Pac Symp Biocomput. 2025;30:473-87. PubMed PMID: 39670390; PubMed Central PMCID: PMC11687821.","DOI":"10.1142\/9789819807024_0034"},{"key":"10.32074\/1591-951X-1531_ref38","doi-asserted-by":"crossref","unstructured":"Gerosa R, De Sanctis R, Jacobs F, et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol Hematol. 2024;196:104324. Epub 20240308. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104324. PubMed PMID: 38462150.","DOI":"10.1016\/j.critrevonc.2024.104324"},{"key":"10.32074\/1591-951X-1531_ref39","doi-asserted-by":"crossref","unstructured":"De Angelis C, Fu X, Cataldo ML, et al. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4\/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021;27(17):4870-82. Epub 20210203. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-4191. PubMed PMID: 33536276; PubMed Central PMCID: PMC8628647.","DOI":"10.1158\/1078-0432.CCR-19-4191"},{"key":"10.32074\/1591-951X-1531_ref40","doi-asserted-by":"crossref","unstructured":"Yu S, Si Y, Xu M, et al. Downregulation of the splicing regulator NSRP1 confers resistance to CDK4\/6 inhibitors via activation of interferon signaling in breast cancer. J Biol Chem. 2025;301(1):108070. Epub 20241210. https:\/\/doi.org\/10.1016\/j.jbc.2024.108070. PubMed PMID: 39667501; PubMed Central PMCID: PMC11750474.","DOI":"10.1016\/j.jbc.2024.108070"},{"key":"10.32074\/1591-951X-1531_ref41","unstructured":"Jansen VM, Bhola NE, Bauer JA, et al. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4\/6 Inhibition in ER-Positive Breast Cancer. Cancer Res. 2017;77(9):2488-99. Epub 20170301. https:\/\/doi.org\/10.1158\/0008-5472.can-16-2653. PubMed PMID: 28249908; PubMed Central PMCID: PMC5421398."},{"key":"10.32074\/1591-951X-1531_ref42","doi-asserted-by":"crossref","unstructured":"Jeselsohn R, Schiff R, Grinshpun A. Restoring order at the cell cycle border: Co-targeting CDK4\/6 and CDK2. Cancer Cell. 2021;39(10):1302-5. Epub 20210909. https:\/\/doi.org\/10.1016\/j.ccell.2021.08.007. PubMed PMID: 34506738.","DOI":"10.1016\/j.ccell.2021.08.007"},{"key":"10.32074\/1591-951X-1531_ref43","doi-asserted-by":"crossref","unstructured":"Segatto I, Mattevi MC, Rampioni Vinciguerra GL, et al. A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4\/6 inhibitors. J Pathol. 2024;264(4):434-47. Epub 20241025. https:\/\/doi.org\/10.1002\/path.6358. PubMed PMID: 39449657.","DOI":"10.1002\/path.6358"},{"key":"10.32074\/1591-951X-1531_ref44","doi-asserted-by":"crossref","unstructured":"Costa C, Wang Y, Ly A, et al. PTEN Loss Mediates Clinical Cross-Resistance to CDK4\/6 and PI3K\u03b1 Inhibitors in Breast Cancer. Cancer Discov. 2020;10(1):72-85. Epub 20191008. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0830. PubMed PMID: 31594766.","DOI":"10.1158\/2159-8290.CD-18-0830"},{"key":"10.32074\/1591-951X-1531_ref45","doi-asserted-by":"crossref","unstructured":"Dunn S, Eberlein C, Yu J, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3K\u03b2\/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene. 2022;41(46):5046-60. Epub 20221014. https:\/\/doi.org\/10.1038\/s41388-022-02482-9. PubMed PMID: 36241868; PubMed Central PMCID: PMC9652152.","DOI":"10.1038\/s41388-022-02482-9"},{"key":"10.32074\/1591-951X-1531_ref46","doi-asserted-by":"crossref","unstructured":"Fusco N, Malapelle U, Fassan M, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Front Oncol. 2021;11:644737. Epub 20210325. https:\/\/doi.org\/10.3389\/fonc.2021.644737. PubMed PMID: 33842357; PubMed Central PMCID: PMC8027489.","DOI":"10.3389\/fonc.2021.644737"},{"key":"10.32074\/1591-951X-1531_ref47","doi-asserted-by":"crossref","unstructured":"Del Re M, Crucitta S, Lorenzini G, et al. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4\/6 inhibitors in metastatic breast cancer patients. Pharmacol Res. 2021;163:105241. Epub 20201010. https:\/\/doi.org\/10.1016\/j.phrs.2020.105241. PubMed PMID: 33049397.","DOI":"10.1016\/j.phrs.2020.105241"},{"key":"10.32074\/1591-951X-1531_ref48","doi-asserted-by":"crossref","unstructured":"Shariati M, Evans KW, Zheng X, et al. Combined inhibition of DDR1 and CDK4\/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA\/AKT1 mutations. Oncogene. 2021;40(26):4425-39. Epub 20210609. https:\/\/doi.org\/10.1038\/s41388-021-01819-0. PubMed PMID: 34108622.","DOI":"10.1038\/s41388-021-01819-0"},{"key":"10.32074\/1591-951X-1531_ref49","doi-asserted-by":"crossref","unstructured":"Huw LY, O\u2019Brien C, Pandita A, et al. Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis. 2013;2(12):e83. Epub 20131223. https:\/\/doi.org\/10.1038\/oncsis.2013.46. PubMed PMID: 24366379; PubMed Central PMCID: PMC3940863.","DOI":"10.1038\/oncsis.2013.46"},{"key":"10.32074\/1591-951X-1531_ref50","doi-asserted-by":"crossref","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573-83. Epub 20150630. https:\/\/doi.org\/10.1038\/nrclinonc.2015.117. PubMed PMID: 26122181; PubMed Central PMCID: PMC4911210.","DOI":"10.1038\/nrclinonc.2015.117"},{"key":"10.32074\/1591-951X-1531_ref51","doi-asserted-by":"crossref","unstructured":"Reinert T, Gon\u00e7alves R, Bines J. Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer. Curr Treat Options Oncol. 2018;19(5):24. Epub 20180417. https:\/\/doi.org\/10.1007\/s11864-018-0542-0. PubMed PMID: 29666928.","DOI":"10.1007\/s11864-018-0542-0"},{"key":"10.32074\/1591-951X-1531_ref52","doi-asserted-by":"crossref","unstructured":"Venetis K, Pepe F, Pescia C, et al. ESR1 mutations in HR+\/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing. Cancer Treat Rev. 2023;121:102642. Epub 20231013. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102642. PubMed PMID: 37864956.","DOI":"10.1016\/j.ctrv.2023.102642"},{"key":"10.32074\/1591-951X-1531_ref53","doi-asserted-by":"crossref","unstructured":"Guerini-Rocco E, Venetis K, Cursano G, et al. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+\/HER2- metastatic breast cancer. Crit Rev Oncol Hematol. 2024;201:104427. Epub 20240623. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104427. PubMed PMID: 38917944.","DOI":"10.1016\/j.critrevonc.2024.104427"},{"key":"10.32074\/1591-951X-1531_ref54","doi-asserted-by":"crossref","unstructured":"Zundelevich A, Dadiani M, Kahana-Edwin S, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22(1):16. Epub 20200203. https:\/\/doi.org\/10.1186\/s13058-020-1246-5. PubMed PMID: 32014063; PubMed Central PMCID: PMC6998824.","DOI":"10.1186\/s13058-020-1246-5"},{"key":"10.32074\/1591-951X-1531_ref55","doi-asserted-by":"crossref","unstructured":"Marra A, Trapani D, Ferraro E, Curigliano G. Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Cancer Treat Res. 2023;188:219-35. https:\/\/doi.org\/10.1007\/978-3-031-33602-7_9. PubMed PMID: 38175348.","DOI":"10.1007\/978-3-031-33602-7_9"},{"key":"10.32074\/1591-951X-1531_ref56","doi-asserted-by":"crossref","unstructured":"Giuliano M, Schifp R, Osborne CK, Trivedi MV. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011;20 Suppl 3:S42-9. https:\/\/doi.org\/10.1016\/s0960-9776(11)70293-4. PubMed PMID: 22015292.","DOI":"10.1016\/S0960-9776(11)70293-4"},{"key":"10.32074\/1591-951X-1531_ref57","doi-asserted-by":"crossref","unstructured":"Wander SA, Cohen O, Gong X, et al. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4\/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020;10(8):1174-93. Epub 20200513. https:\/\/doi.org\/10.1158\/2159-8290.cd-19-1390. PubMed PMID: 32404308; PubMed Central PMCID: PMC8815415.","DOI":"10.1158\/2159-8290.CD-19-1390"},{"key":"10.32074\/1591-951X-1531_ref58","doi-asserted-by":"crossref","unstructured":"Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-41. Epub 20100409. https:\/\/doi.org\/10.1038\/nrm2882. PubMed PMID: 20379207.","DOI":"10.1038\/nrm2882"},{"key":"10.32074\/1591-951X-1531_ref59","doi-asserted-by":"crossref","unstructured":"Nieto-Coronel T, Alette OG, Yacab R, et al. PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects. Int J Breast Cancer. 2024;2024:9058033. Epub 20241015. https:\/\/doi.org\/10.1155\/2024\/9058033. PubMed PMID: 39444377; PubMed Central PMCID: PMC11496583.","DOI":"10.1155\/2024\/9058033"},{"key":"10.32074\/1591-951X-1531_ref60","unstructured":"Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2\u2020. Ann Oncol. 2014;25(12):2357-62. Epub 20140917. https:\/\/doi.org\/10.1093\/annonc\/mdu456. PubMed PMID: 25231953; PubMed Central PMCID: PMC6267855."},{"key":"10.32074\/1591-951X-1531_ref61","unstructured":"Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904-16. Epub 20170530. https:\/\/doi.org\/10.1016\/s1470-2045(17)30376-5. PubMed PMID: 28576675; PubMed Central PMCID: PMC5549667."},{"key":"10.32074\/1591-951X-1531_ref62","doi-asserted-by":"crossref","unstructured":"Bello Roufai D, Gon\u00e7alves A, De La Motte Rouge T, et al. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene. 2023;42(23):1951-6. Epub 20230107. https:\/\/doi.org\/10.1038\/s41388-022-02585-3. PubMed PMID: 36611120.","DOI":"10.1038\/s41388-022-02585-3"},{"key":"10.32074\/1591-951X-1531_ref63","doi-asserted-by":"crossref","unstructured":"Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-70. https:\/\/doi.org\/10.1056\/NEJMoa2214131. PubMed PMID: 37256976; PubMed Central PMCID: PMC11335038.","DOI":"10.1056\/NEJMoa2214131"},{"key":"10.32074\/1591-951X-1531_ref64","doi-asserted-by":"crossref","unstructured":"Andrahennadi S, Sami A, Haider K, et al. Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience. Cancers (Basel). 2021;13(16). Epub 20210819. https:\/\/doi.org\/10.3390\/cancers13164163. PubMed PMID: 34439317; PubMed Central PMCID: PMC8391338.","DOI":"10.3390\/cancers13164163"},{"key":"10.32074\/1591-951X-1531_ref65","doi-asserted-by":"crossref","unstructured":"Gheysen M, Punie K, Wildiers H, Neven P. Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. Cancer Treat Rev. 2024;130:102825. Epub 20240911. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102825. PubMed PMID: 39293125.","DOI":"10.1016\/j.ctrv.2024.102825"},{"key":"10.32074\/1591-951X-1531_ref66","doi-asserted-by":"crossref","unstructured":"Chinnasamy K, Saravanan M, Poomani K. Investigation of binding mechanism and downregulation of elacestrant for wild and L536S mutant estrogen receptor-\u03b1 through molecular dynamics simulation and binding free energy analysis. J Comput Chem. 2020;41(2):97-109. Epub 20191010. https:\/\/doi.org\/10.1002\/jcc.26076. PubMed PMID: 31602686.","DOI":"10.1002\/jcc.26076"},{"key":"10.32074\/1591-951X-1531_ref67","doi-asserted-by":"crossref","unstructured":"Bidard F-C, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246-56. https:\/\/doi.org\/10.1200\/JCO.22.00338. PubMed Central PMCID: PMC9553388.","DOI":"10.1200\/JCO.22.00338"},{"key":"10.32074\/1591-951X-1531_ref68","doi-asserted-by":"crossref","unstructured":"Oliveira M, Pominchuk D, Nowecki Z, et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024;25(11):1424-39. https:\/\/doi.org\/10.1016\/s1470-2045(24)00387-5. PubMed PMID: 39481395.","DOI":"10.1016\/S1470-2045(24)00387-5"},{"key":"10.32074\/1591-951X-1531_ref69","doi-asserted-by":"crossref","unstructured":"Turner N, Huang-Bartlett C, Kalinsky K, et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023;19(8):559-73. Epub 20230418. https:\/\/doi.org\/10.2217\/fon-2022-1196. PubMed PMID: 37070653.","DOI":"10.2217\/fon-2022-1196"},{"key":"10.32074\/1591-951X-1531_ref70","doi-asserted-by":"crossref","unstructured":"Garcia-Fructuoso I, Gomez-Bravo R, Schettini F. Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment. Curr Opin Oncol. 2022;34(6):635-42. Epub 20220824. https:\/\/doi.org\/10.1097\/cco.0000000000000892. PubMed PMID: 36000362.","DOI":"10.1097\/CCO.0000000000000892"},{"key":"10.32074\/1591-951X-1531_ref71","doi-asserted-by":"crossref","unstructured":"Neupane N, Bawek S, Gurusinghe S, et al. Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers (Basel). 2024;16(3). Epub 20240131. https:\/\/doi.org\/10.3390\/cancers16030619. PubMed PMID: 38339371; PubMed Central PMCID: PMC10854647.","DOI":"10.3390\/cancers16030619"},{"key":"10.32074\/1591-951X-1531_ref72","doi-asserted-by":"crossref","unstructured":"Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J Pers Med. 2018;8(3). Epub 20180917. https:\/\/doi.org\/10.3390\/jpm8030030. PubMed PMID: 30227640; PubMed Central PMCID: PMC6164147.","DOI":"10.3390\/jpm8030030"},{"key":"10.32074\/1591-951X-1531_ref73","doi-asserted-by":"crossref","unstructured":"Malapelle U, Fassan M, de Biase D. Special Issue: Next-Generation Sequencing in Tumor Diagnosis and Treatment II. Diagnostics (Basel). 12. Switzerland2022.","DOI":"10.3390\/diagnostics12082017"},{"key":"10.32074\/1591-951X-1531_ref74","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez J, Avila J, Rolfo C, et al. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther. 2021;9(1):89-110. Epub 20210310. https:\/\/doi.org\/10.1007\/s40487-021-00144-6. PubMed PMID: 33689160; PubMed Central PMCID: PMC8140006.","DOI":"10.1007\/s40487-021-00144-6"},{"key":"10.32074\/1591-951X-1531_ref75","doi-asserted-by":"crossref","unstructured":"Kobayashi N, Miura K, Kaneko A, et al. Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes. Cancers (Basel). 2023;15(21). Epub 20231031. https:\/\/doi.org\/10.3390\/cancers15215248. PubMed PMID: 37958421; PubMed Central PMCID: PMC10648983.","DOI":"10.3390\/cancers15215248"},{"key":"10.32074\/1591-951X-1531_ref76","doi-asserted-by":"crossref","unstructured":"Raez LE, Brice K, Dumais K, et al. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2023;24(2):120-9. Epub 20221125. https:\/\/doi.org\/10.1016\/j.cllc.2022.11.007. PubMed PMID: 36585341.","DOI":"10.1016\/j.cllc.2022.11.007"},{"key":"10.32074\/1591-951X-1531_ref77","doi-asserted-by":"crossref","unstructured":"Jennings LJ, Arcila ME, Corless C, et al. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341-65. Epub 20170321. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.01.011. PubMed PMID: 28341590; PubMed Central PMCID: PMC6941185.","DOI":"10.1016\/j.jmoldx.2017.01.011"},{"key":"10.32074\/1591-951X-1531_ref78","doi-asserted-by":"crossref","unstructured":"Vestergaard LK, Oliveira DNP, Poulsen TS, H\u00f8gdall CK, H\u00f8gdall EV. Oncomine\u2122 Comprehensive Assay v3 vs. Oncomine\u2122 Comprehensive Assay Plus. Cancers (Basel). 2021;13(20). Epub 20211018. https:\/\/doi.org\/10.3390\/cancers13205230. PubMed PMID: 34680378; PubMed Central PMCID: PMC8533843.","DOI":"10.3390\/cancers13205230"},{"key":"10.32074\/1591-951X-1531_ref79","doi-asserted-by":"crossref","unstructured":"Hynes SO, Pang B, James JA, Maxwell P, Salto-Tellez M. Tissue-based next generation sequencing: application in a universal healthcare system. Br J Cancer. 2017;116(5):553-60. Epub 20170119. https:\/\/doi.org\/10.1038\/bjc.2016.452. PubMed PMID: 28103613; PubMed Central PMCID: PMC5344287.","DOI":"10.1038\/bjc.2016.452"},{"key":"10.32074\/1591-951X-1531_ref80","doi-asserted-by":"crossref","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology. 2021;32(12):1475-95. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"10.32074\/1591-951X-1531_ref81","doi-asserted-by":"crossref","unstructured":"Kerr KM, Bibeau F, Thunnissen E, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. 2021;154:161-75. Epub 20210222. https:\/\/doi.org\/10.1016\/j.lungcan.2021.02.026. PubMed PMID: 33690091.","DOI":"10.1016\/j.lungcan.2021.02.026"},{"key":"10.32074\/1591-951X-1531_ref82","doi-asserted-by":"crossref","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588-606. Epub 20240527. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005. PubMed PMID: 38834388.","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"10.32074\/1591-951X-1531_ref83","doi-asserted-by":"crossref","unstructured":"Ulahannan D, Kovac MB, Mulholland PJ, Cazier JB, Tomlinson I. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer. 2013;109(4):827-35. Epub 20130725. https:\/\/doi.org\/10.1038\/bjc.2013.416. PubMed PMID: 23887607; PubMed Central PMCID: PMC3749581.","DOI":"10.1038\/bjc.2013.416"},{"key":"10.32074\/1591-951X-1531_ref84","doi-asserted-by":"crossref","unstructured":"Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020. Epub 2020\/08\/28. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014. PubMed PMID: 32853681.","DOI":"10.1016\/j.annonc.2020.07.014"},{"key":"10.32074\/1591-951X-1531_ref85","doi-asserted-by":"crossref","unstructured":"Jacobson A. Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+\/HER2- Advanced Breast Cancer. Oncologist. 2022;27(Suppl 1):S13-s4. https:\/\/doi.org\/10.1093\/oncolo\/oyac011. PubMed PMID: 35348782; PubMed Central PMCID: PMC8963159.","DOI":"10.1093\/oncolo\/oyac011"},{"key":"10.32074\/1591-951X-1531_ref86","doi-asserted-by":"crossref","unstructured":"Bhave MA, Quintanilha JCF, Tukachinsky H, et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat. 2024;207(3):599-609. Epub 20240614. https:\/\/doi.org\/10.1007\/s10549-024-07376-w. PubMed PMID: 38872062; PubMed Central PMCID: PMC11420341.","DOI":"10.1007\/s10549-024-07376-w"},{"key":"10.32074\/1591-951X-1531_ref87","doi-asserted-by":"crossref","unstructured":"Bardia A, Cort\u00e9s J, Bidard FC, et al. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4\/6 Inhibitor and in Clinical Subgroups. Clin Cancer Res. 2024;30(19):4299-309. https:\/\/doi.org\/10.1158\/1078-0432.ccr-24-1073. PubMed PMID: 39087959; PubMed Central PMCID: PMC11443208.","DOI":"10.1158\/1078-0432.CCR-24-1073"},{"key":"10.32074\/1591-951X-1531_ref88","doi-asserted-by":"crossref","unstructured":"Fanucci K, Giordano A, Erick T, Tolaney SM, Sammons S. Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT)\/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive\/human epidermal growth factor receptor 2 (HER2)-negative (HR+\/HER2-) advanced breast cancer. ESMO Open. 2024;9(12):103997. Epub 20241213. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103997. PubMed PMID: 39674130; PubMed Central PMCID: PMC11699375.","DOI":"10.1016\/j.esmoop.2024.103997"},{"key":"10.32074\/1591-951X-1531_ref89","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-S\u00e1ez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45. Epub 20200513. https:\/\/doi.org\/10.1186\/s13058-020-01284-9. PubMed PMID: 32404150; PubMed Central PMCID: PMC7222307.","DOI":"10.1186\/s13058-020-01284-9"},{"key":"10.32074\/1591-951X-1531_ref90","unstructured":"Satam H, Joshi K, Mangrolia U, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology (Basel). 2023;12(7). Epub 20230713. https:\/\/doi.org\/10.3390\/biology12070997. PubMed PMID: 37508427; PubMed Central PMCID: PMC10376292."},{"key":"10.32074\/1591-951X-1531_ref91","doi-asserted-by":"crossref","unstructured":"Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol. 2019;30(Suppl_10):x3-x11. Epub 2019\/12\/21. https:\/\/doi.org\/10.1093\/annonc\/mdz281. PubMed PMID: 31859348; PubMed Central PMCID: PMC6923788.","DOI":"10.1093\/annonc\/mdz281"},{"key":"10.32074\/1591-951X-1531_ref92","doi-asserted-by":"crossref","unstructured":"Cimino-Mathews A. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. Mod Pathol. 2021;34(Suppl 1):62-77. Epub 20201027. https:\/\/doi.org\/10.1038\/s41379-020-00697-3. PubMed PMID: 33110239.","DOI":"10.1038\/s41379-020-00697-3"},{"key":"10.32074\/1591-951X-1531_ref93","unstructured":"Ciardiello D, Martini G, Famiglietti V, et al. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers (Basel). 2021;13(8). Epub 20210417. https:\/\/doi.org\/10.3390\/cancers13081941. PubMed PMID: 33920531; PubMed Central PMCID: PMC8073594."},{"key":"10.32074\/1591-951X-1531_ref94","doi-asserted-by":"crossref","unstructured":"Freitas AJA, Causin RL, Varuzza MB, et al. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. Int J Mol Sci. 2022;23(17). Epub 20220901. https:\/\/doi.org\/10.3390\/ijms23179952. PubMed PMID: 36077348; PubMed Central PMCID: PMC9456236.","DOI":"10.3390\/ijms23179952"},{"key":"10.32074\/1591-951X-1531_ref95","doi-asserted-by":"crossref","unstructured":"Guo L, Kong D, Liu J, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12(1):3. Epub 20230109. https:\/\/doi.org\/10.1186\/s40164-022-00363-1. PubMed PMID: 36624542; PubMed Central PMCID: PMC9830930.","DOI":"10.1186\/s40164-022-00363-1"},{"key":"10.32074\/1591-951X-1531_ref96","doi-asserted-by":"crossref","unstructured":"Krebs MG, Malapelle U, Andr\u00e9 F, et al. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. JAMA Oncol. 2022;8(12):1830-9. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4457. PubMed PMID: 36264554.","DOI":"10.1001\/jamaoncol.2022.4457"},{"key":"10.32074\/1591-951X-1531_ref97","doi-asserted-by":"crossref","unstructured":"Pisapia P, Iaccarino A, Troncone G, Malapelle U. Liquid Biopsy in Solid Tumours: An Overview. Cytopathology. 2025. Epub 20250411. https:\/\/doi.org\/10.1111\/cyt.13485. PubMed PMID: 40219616.","DOI":"10.1111\/cyt.13485"},{"key":"10.32074\/1591-951X-1531_ref98","doi-asserted-by":"crossref","unstructured":"Ozyurt R, Ozpolat B. Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. Cancers (Basel). 2022;14(21). Epub 20221024. https:\/\/doi.org\/10.3390\/cancers14215206. PubMed PMID: 36358625; PubMed Central PMCID: PMC9655708.","DOI":"10.3390\/cancers14215206"},{"key":"10.32074\/1591-951X-1531_ref99","doi-asserted-by":"crossref","unstructured":"Russo A, Incorvaia L, Del Re M, et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. ESMO Open. 2021;6(3):100164. Epub 20210603. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100164. PubMed PMID: 34091263; PubMed Central PMCID: PMC8182269.","DOI":"10.1016\/j.esmoop.2021.100164"},{"key":"10.32074\/1591-951X-1531_ref100","doi-asserted-by":"crossref","unstructured":"Andre F, Filleron T, Kamal M, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022;610(7931):343-8. Epub 20220907. https:\/\/doi.org\/10.1038\/s41586-022-05068-3. PubMed PMID: 36071165.","DOI":"10.1038\/s41586-022-05068-3"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:32:31Z","timestamp":1775737951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":100,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-1531","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"2"}}